What is the recommended treatment for vasculitis?

Vasculitis Treatment

For ANCA-associated vasculitis (the most common systemic vasculitis), initiate remission induction with rituximab or cyclophosphamide combined with reduced-dose glucocorticoids, followed by rituximab for maintenance therapy.

Treatment Algorithm by Disease Severity and Type

ANCA-Associated Vasculitis (GPA/MPA)

Severe Disease (organ- or life-threatening manifestations)

Remission Induction:

• Rituximab OR cyclophosphamide combined with glucocorticoids 1, 2
• Use reduced-dose glucocorticoid regimen (starting with 3 days of IV methylprednisolone pulses up to 3g total, followed by 1 week high-dose oral steroids) rather than standard-dose (1 mg/kg/day) 1
  • This provides similar efficacy for preventing ESRD or death but with decreased infection risk
  • Minimizing glucocorticoid exposure is critical given known long-term toxicities

Special Considerations:

• Plasma exchange may be considered for patients with severe renal vasculitis (rapidly progressive glomerulonephritis) or alveolar hemorrhage, though evidence is conditional 1, 3
• Can also serve as salvage therapy for critically ill patients not responding to standard induction 1

Remission Maintenance:

• Rituximab is preferred over azathioprine or methotrexate for at least 48 months from diagnosis 1, 3
  • Rituximab demonstrates lower relapse rates compared to azathioprine 1
  • While methotrexate and azathioprine have more long-term safety data and lower cost, rituximab's superior efficacy takes priority

Non-Severe Disease (no organ- or life-threatening manifestations)

Remission Induction:

• Methotrexate plus glucocorticoids is preferred over cyclophosphamide or rituximab 1
  • Rationale: Reserve more toxic therapies for when truly needed, as non-severe GPA can still require multiple treatment courses
  • Methotrexate has larger evidence base and clinical experience compared to rituximab for this population

When to Consider Rituximab Instead:

• Hepatic or renal dysfunction
• Recurrent relapses on methotrexate
• Compliance concerns 1

Eosinophilic Granulomatosis with Polyangiitis (EGPA)

Severe Disease:

• Cyclophosphamide or rituximab for remission induction 3

Non-Severe Disease:

• Mepolizumab (IL-5 inhibitor) OR azathioprine OR methotrexate OR mycophenolate mofetil 3

Large Vessel Vasculitis (Giant Cell Arteritis, Takayasu Arteritis)

Initial Treatment:

• High-dose glucocorticoids remain the cornerstone 4

Relapsing Disease:

• Tocilizumab has strong evidence for giant cell arteritis 4
• Anti-TNF agents or tocilizumab for Takayasu arteritis 4

Important Caveat: TNF-α blockers are ineffective in giant cell arteritis 4

Critical Pitfalls to Avoid

1. Don't use glucocorticoid monotherapy except in rare circumstances (e.g., isolated arthralgias, intolerance to all other agents) - requires close monitoring 1

2. Don't use standard high-dose glucocorticoids (1 mg/kg/day) when reduced-dose regimens provide equivalent efficacy with less toxicity 1

3. Don't use azathioprine or methotrexate for maintenance in severe GPA/MPA when rituximab is available - higher relapse rates 1

4. Don't delay treatment while awaiting ANCA results - clinical suspicion should drive immediate therapy initiation in severe presentations

Divergence in Evidence

The 2024 EULAR guidelines 2 and 2021 ACR/Vasculitis Foundation guidelines 1 are largely concordant. The main areas requiring further research include:

• Optimal glucocorticoid dosing and duration
• Combination of rituximab plus cyclophosphamide versus rituximab alone
• Role of novel agents like avacopan (C5a inhibitor) and JAK inhibitors
• Optimal rituximab maintenance schedules 2

The most recent 2025 British Society for Rheumatology recommendations 5 align with these approaches, reinforcing the consensus around rituximab-based strategies and glucocorticoid minimization.